阿替利珠单抗不良反应94例文献分析  

Literature analysis of 94 cases of adverse reactions to atezolizumab

作　　者：余萌 周红 承华薇[3] 许荣蓉 孙言才 YU Meng;ZHOU Hong;CHENG Huawei;XU Rongrong;SUN Yancai(College of Pharmacy,Anhui University of Traditional Chinese Medicine,Hefei,Anhui230011,China;Pharmacy Department,The Fourth People's Hospital of Huainan City,Huainan,Anhui 232000,China;Pharmacy Department,Anhui Cancer Hospital,Hefei,Anhui 230031,China)

机构地区：[1]安徽中医药大学药学院,安徽合肥230011 [2]淮南市第四人民医院药剂科,安徽淮南232000 [3]安徽省肿瘤医院药剂科,安徽合肥230031

出　　处：《安徽医药》2024年第1期205-212,共8页Anhui Medical and Pharmaceutical Journal

基　　金：安徽省科技厅面上科技攻关项目(1704e0302204)。

摘　　要：目的分析阿替利珠单抗发生不良反应(adverse reactions,ADRs)的临床特点与规律,为临床安全用药提供参考。方法搜索中国知网、维普、万方、Web of Science、PubMed数据库,收集关于阿替利珠单抗所致不良反应的报道文献并进行分析,研究时间为2022年4—8月。结果阿替利珠致不良反应报道共94例;其中男性56例(59.57%),女性38例(40.43%),男性占比较高;年龄(62.8±12.0)岁,中老年人居多;多数发生在用药后的90 d内(71例,71.0%);阿替利珠单抗致ADRs累及多个系统/器官,其中以神经系统损害(22例,22.0%)占比最多;3~4级严重ADRs占比最多(64例,64.0%);94例经治疗和(或)停药后,好转或治愈80例,死亡5例。结论阿替利珠单抗所致ADRs涉及不同性别与年龄段病人,累及多个系统/器官,临床使用应随时监测,警惕ADRs的发生,做到及时识别与治疗。Objective To analyze the clinical characteristics and patterns of adverse reactions(ADRs)of atezolizumab,and to pro⁃vide a reference for the safety of clinical use of this drug.Methods The CNKI,VIP,Wanfang,Web of Science,and PubMed databases were searched,and the reported literature on adverse reactions caused by atezolizumab was collected and analyzed.The study period was from April 2022 to August 2022.Results A total of 94 cases of atezolizumab-induced ADRs were reported.Among them,56 cases(59.57%)were male and 38 cases(40.43%)were female,with a higher proportion of males.Age(62.8±12.0)years,with the majority of middle-aged and elderly people.Most of them occurred within 90 d after drug administration(71 cases,71.0%).Atezolizumab-induced ADRs involved multiple systems/organs,with neurological damage(22 cases,22.0%)accounting for the largest proportion;grade 3-4 se⁃vere ADRs accounted for the largest proportion(64 cases,64.0%);94 cases improved or were cured in 80 cases after treatment and/or discontinuation of the drug,and 5 cases died.Conclusion ADRs caused by atezolizumab involve patients of different sexes and ages and involve multiple systems/organs.Clinical use should be monitored at all times to be vigilant for the occurrence of ADRs so that they can be recognized and treated in a timely manner.

关 键 词：阿替利珠单抗 药物相关性副作用和不良反应 抗体 单克隆 程序性细胞死亡受体1 

分 类 号：R979.1[医药卫生—药品]